Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease

Frontiers in Aging Neuroscience

Volumn 5, Issue FEB, 2013, Pages

  Irwin, David J ^a   Trojanowski, John Q ^a   Grossman, Murray ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

A 1 42; Alzheimer's disease; Biomarker; Cerebrospinal fluid; Frontotemporal dementia; Primary progressive aphasia; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ALZHEIMER DISEASE; AUTOPSY; CEREBROSPINAL FLUID; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DISEASE SEVERITY; FRONTOTEMPORAL DEMENTIA; HUMAN; LONGITUDINAL STUDY; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84897367849     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2013.00006     Document Type: Review

References (184)

1. Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., et al. (2007). Focal cortical presentations of Alzheimer's disease. Brain 130, 2636-2645.
2. Arai, H., Morikawa, Y., Higuchi, M., Matsui, T., Clark, C. M., Miura, M., et al. (1997). Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct taurelated pathology. Biochem. Biophys. Res. Commun. 236, 262-264.
3. Ash, S., Moore, P., Antani, S., McCawley, G., Work, M., and Grossman, M. (2006). Trying to tell a tale: discourse impairments in progressive aphasia and frontotemporal dementia. Neurology 66, 1405-1413.
4. Ash, S., Moore, P., Vesely, L., Gunawardena, D., McMillan, C., Anderson, C., et al. (2009). Non-Fluent Speech in Frontotemporal Lobar Degeneration. J. Neurolinguistics 22, 370-383.
5. Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., et al. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916-919.
6. Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804.
7. Bian, H., and Grossman, M. (2007). Frontotemporal lobar degeneration: recent progress in antemortem diagnosis. Acta Neuropathol. 114, 23-29.
8. Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., et al. (2008). CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70, 1827-1835.
9. Bibl, M., Gallus, M., Welge, V., Esselmann, H., Wolf, S., Ruther, E., et al. (2012). Cerebrospinal fluid amyloid-beta 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J. Neural Transm. 119, 805-813.
10. Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H., Wolf, S., Otto, M., et al. (2011). Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement. Geriatr. Cogn. Disord. 31, 37-44.
11. Bibl, M., Mollenhauer, B., Wolf, S., Esselmann, H., Lewczuk, P., Kornhuber, J., et al. (2007). Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations. J. Neural Transm. 114, 621-628.
12. Blennow, K., Wallin, A., Agren, H., Spenger, C., Siegfried, J., and Vanmechelen, E. (1995). Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231-245.
13. Borroni, B., Gardoni, F., Parnetti, L., Magno, L., Malinverno, M., Saggese, E., et al. (2009). Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol. Aging 30, 34-40.
14. Borroni, B., Malinverno, M., Gardoni, F., Alberici, A., Parnetti, L., Premi, E., et al. (2008). Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71, 1796-1803.
15. Borroni, B., Malinverno, M., Gardoni, F., Grassi, M., Parnetti, L., Agosti, C., et al. (2010). A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy. J. Alzheimers Dis. 22, 195-203.
16. Boxer, A. L., Gold, M., Huey, E., Gao, F. B., Burton, E. A., Chow, T., et al. (2012a). Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. doi: 10.1016/j.jalz.2012.03.002. [Epub ahead of print].
17. Boxer, A. L., Gold, M., Huey, E., Hu, W. T., Rosen, H., Kramer, J., et al. (2012b). The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. doi: 10.1016/j.jalz.2012.03.003. [Epub ahead of print].
18. Brunnstrom, H., Rawshani, N., Zetterberg, H., Blennow, K., Minthon, L., Passant, U., et al. (2010). Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement. 6, 104-109.
19. Buerger, K., Teipel, S. J., Zinkowski, R., Blennow, K., Arai, H., Engel, R., et al. (2002a). CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59, 627-629.
20. Buerger, K., Zinkowski, R., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., et al. (2002b). Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59, 1267-1272.
21. Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., et al. (2003). Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 60, 1696-1702.
22. Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., et al. (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2:252. doi: 10.1038/ncomms1255
23. Cruts, M., Gijselinck, I., Van Der Zee, J., Engelborghs, S., Wils, H., Pirici, D., et al. (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924.
24. Davis, D. G., Schmitt, F. A., Wekstein, D. R., and Markesbery, W. R. (1999). Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 58, 376-388.
25. De Jong, D., Jansen, R. W., Pijnenburg, Y. A., Van Geel, W. J., Borm, G. F., Kremer, H. P., et al. (2007). CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78, 936-938.
26. De Meyer, G., Shapiro, F., Vanderstichele, H., Vanmechelen, E., Engelborghs, S., De Deyn, P. P., et al. (2010). Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949-956.
27. De Souza, L. C., Lamari, F., Belliard, S., Jardel, C., Houillier, C., De Paz, R., et al. (2011). Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J. Neurol. Neurosurg. Psychiatry 82, 240-246.
28. Dejesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256.
29. Dickson, D. (2004). "Sporadic tauopaties: Pick's disease, corticobasal degeneration, progressive supranuclear palsy and argyrophilic grain disease," in The Neuropathology of Dementia 2nd Edn, eds M. Esiri, V. M-Y. Lee, and J. Q. Trojanowski (New York, NY: Cambridge University Press), 227-256.
30. Engelborghs, S., De Vreese, K., Van De Casteele, T., Vanderstichele, H., Van Everbroeck, B., Cras, P., et al. (2008). Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29, 1143-1159.
31. Engelborghs, S., Maertens, K., Vloeberghs, E., Aerts, T., Somers, N., Marien, P., et al. (2006). Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem. Int. 48, 286-295.
32. Eslinger, P. J., Moore, P., Antani, S., Anderson, C., and Grossman, M. (2012). Apathy in frontotemporal dementia: behavioral and neuroimaging correlates. Behav. Neurol. 25, 127-136.
33. Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S. Y., Dence, C. S., Shah, A. R., et al. (2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512-519.
34. Fagan, A. M., Shaw, L. M., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., et al. (2011). Comparison of analytical platforms for cerebrospinal fluid measures of {beta}-amyloid 1-42, total tau, and P-tau181 for identifying alzheimer disease amyloid plaque pathology. Arch. Neurol. 68, 1137-1144.
35. Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., et al. (2006). Frontotemporal dementia: clinicopathological correlations. Ann. Neurol. 59, 952-962.
36. Foulds, P., McAuley, E., Gibbons, L., Davidson, Y., Pickering-Brown, S. M., Neary, D., et al. (2008). TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol. 116, 141-146.
37. Gabelle, A., Roche, S., Geny, C., Bennys, K., Labauge, P., Tholance, Y., et al. (2011). Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J. Alzheimers Dis. 26, 553-563.
38. Geser, F., Brandmeir, N. J., Kwong, L. K., Martinez-Lage, M., Elman, L., McCluskey, L., et al. (2008). Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch. Neurol. 65, 636-641.
39. Geser, F., Martinez-Lage, M., Robinson, J., Uryu, K., Neumann, M., Brandmeir, N. J., et al. (2009). Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch. Neurol. 66, 180-189.
40. Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M., and Binetti, G. (2008). Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71, 1235-1239.
41. Gorno-Tempini, M. L., Brambati, S. M., Ginex, V., Ogar, J., Dronkers, N. F., Marcone, A., et al. (2008). The logopenic/phonological variant of primary progressive aphasia. Neurology 71, 1227-1234.
42. Buerger, K., Teipel, S. J., Zinkowski, R., Blennow, K., Arai, H., Engel, R., et al. (2002a). CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59, 627-629.
43. Buerger, K., Zinkowski, R., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., et al. (2002b). Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59, 1267-1272.
44. Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., et al. (2003). Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 60, 1696-1702.
45. Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., et al. (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2:252. doi: 10.1038/ncomms1255
46. Cruts, M., Gijselinck, I., Van Der Zee, J., Engelborghs, S., Wils, H., Pirici, D., et al. (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924.
47. Davis, D. G., Schmitt, F. A., Wekstein, D. R., and Markesbery, W. R. (1999). Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 58, 376-388.
48. De Jong, D., Jansen, R. W., Pijnenburg, Y. A., Van Geel, W. J., Borm, G. F., Kremer, H. P., et al. (2007). CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78, 936-938.
49. De Meyer, G., Shapiro, F., Vanderstichele, H., Vanmechelen, E., Engelborghs, S., De Deyn, P. P., et al. (2010). Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949-956.
50. De Souza, L. C., Lamari, F., Belliard, S., Jardel, C., Houillier, C., De Paz, R., et al. (2011). Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J. Neurol. Neurosurg. Psychiatry 82, 240-246.
51. Dejesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256.
52. Dickson, D. (2004). "Sporadic tauopaties: Pick's disease, corticobasal degeneration, progressive supranuclear palsy and argyrophilic grain disease," in The Neuropathology of Dementia 2nd Edn, eds M. Esiri, V. M-Y. Lee, and J. Q. Trojanowski (New York, NY: Cambridge University Press), 227-256.
53. Engelborghs, S., De Vreese, K., Van De Casteele, T., Vanderstichele, H., Van Everbroeck, B., Cras, P., et al. (2008). Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29, 1143-1159.
54. Engelborghs, S., Maertens, K., Vloeberghs, E., Aerts, T., Somers, N., Marien, P., et al. (2006). Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem. Int. 48, 286-295.
55. Eslinger, P. J., Moore, P., Antani, S., Anderson, C., and Grossman, M. (2012). Apathy in frontotemporal dementia: behavioral and neuroimaging correlates. Behav. Neurol. 25, 127-136.
56. Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S. Y., Dence, C. S., Shah, A. R., et al. (2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512-519.
57. Fagan, A. M., Shaw, L. M., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., et al. (2011). Comparison of analytical platforms for cerebrospinal fluid measures of {beta}-amyloid 1-42, total tau, and P-tau181 for identifying alzheimer disease amyloid plaque pathology. Arch. Neurol. 68, 1137-1144.
58. Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., et al. (2006). Frontotemporal dementia: clinicopathological correlations. Ann. Neurol. 59, 952-962.
59. Foulds, P., McAuley, E., Gibbons, L., Davidson, Y., Pickering-Brown, S. M., Neary, D., et al. (2008). TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol. 116, 141-146.
60. Gabelle, A., Roche, S., Geny, C., Bennys, K., Labauge, P., Tholance, Y., et al. (2011). Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J. Alzheimers Dis. 26, 553-563.
61. Geser, F., Brandmeir, N. J., Kwong, L. K., Martinez-Lage, M., Elman, L., McCluskey, L., et al. (2008). Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch. Neurol. 65, 636-641.
62. Geser, F., Martinez-Lage, M., Robinson, J., Uryu, K., Neumann, M., Brandmeir, N. J., et al. (2009). Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch. Neurol. 66, 180-189.
63. Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M., and Binetti, G. (2008). Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71, 1235-1239.
64. Gorno-Tempini, M. L., Brambati, S. M., Ginex, V., Ogar, J., Dronkers, N. F., Marcone, A., et al. (2008). The logopenic/phonological variant of primary progressive aphasia. Neurology 71, 1227-1234.
65. Gorno-Tempini, M. L., Dronkers, N. F., Rankin, K. P., Ogar, J. M., Phengrasamy, L., Rosen, H. J., et al. (2004). Cognition and anatomy in three variants of primary progressive aphasia. Ann. Neurol. 55, 335-346.
66. Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., et al. (2011). Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014.
67. Green, A. J., Harvey, R. J., Thompson, E. J., and Rossor, M. N. (1999). Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 259, 133-135.
68. Grossman, M. (2010). Primary progressive aphasia: clinicopathological correlations. Nat. Rev. Neurol. 6, 88-97.
69. Grossman, M., Eslinger, P. J., Troiani, V., Anderson, C., Avants, B., Gee, J. C., et al. (2010). The role of ventral medial prefrontal cortex in social decisions: converging evidence from fMRI and frontotemporal lobar degeneration. Neuropsychologia 48, 3505-3512.
70. Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., et al. (2005). Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 57, 721-729.
71. Grossman, M., Powers, J., Ash, S., McMillan, C., Burkholder, L., Irwin, D., et al. (2012). Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. Brain Lang. doi: 10.1016/j.bandl.2012.10.005. [Epub ahead of print].
72. Grossman, M., Xie, S. X., Libon, D. J., Wang, X., Massimo, L., Moore, P., et al. (2008). Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology 70, 2036-2045.
73. Gunawardena, D., Ash, S., McMillan, C., Avants, B., Gee, J., and Grossman, M. (2010). Why are patients with progressive nonfluent aphasia nonfluent? Neurology 75, 588-594.
74. Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., and Trojanowski, J. Q. (2010). Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45, 30-40.
75. Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P., et al. (2000). Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimers Dis. 2, 199-206.
76. Hodges, J. R., Davies, R. R., Xuereb, J. H., Casey, B., Broe, M., Bak, T. H., et al. (2004). Clinicopathological correlates in frontotemporal dementia. Ann. Neurol. 56, 399-406.
77. Hodges, J. R., and Patterson, K. (2007). Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 6, 1004-1014.
78. Hoglinger, G. U., Melhem, N. M., Dickson, D. W., Sleiman, P. M., Wang, L. S., Klei, L., et al. (2011). Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699-705.
79. Hu, W. T., Chen-Plotkin, A., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M., et al. (2010a). Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 120, 385-399.
80. Hu, W. T., Chen-Plotkin, A., Grossman, M., Arnold, S. E., Clark, C. M., Shaw, L. M., et al. (2010b). Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 75, 2079-2086.
81. Hu, W. T., McMillan, C., Libon, D., Leight, S., Forman, M., Lee, V. M., et al. (2010c). Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology 75, 595-602.
82. Hu, W. T., Trojanowski, J. Q., and Shaw, L. M. (2011). Biomarkers in frontotemporal lobar degenerations-progress and challenges. Prog. Neurobiol. 95, 636-648.
83. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al. (1998). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
84. Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M., et al. (2012a). Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135, 807-818.
85. Irwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L. S., et al. (2012b). Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch. Neurol. 69, 1018-1025.
86. Irwin, D. J., McMillan, C. T., Brettschneider, J., Libon, D. J., Powers, J., Rascovsky, K., et al. (2013). Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 84, 163-169.
87. Jack, C. R. Jr., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128.
88. Gorno-Tempini, M. L., Dronkers, N. F., Rankin, K. P., Ogar, J. M., Phengrasamy, L., Rosen, H. J., et al. (2004). Cognition and anatomy in three variants of primary progressive aphasia. Ann. Neurol. 55, 335-346.
89. Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., et al. (2011). Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014.
90. Green, A. J., Harvey, R. J., Thompson, E. J., and Rossor, M. N. (1999). Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 259, 133-135.
91. Grossman, M. (2010). Primary progressive aphasia: clinicopathological correlations. Nat. Rev. Neurol. 6, 88-97.
92. Grossman, M., Eslinger, P. J., Troiani, V., Anderson, C., Avants, B., Gee, J. C., et al. (2010). The role of ventral medial prefrontal cortex in social decisions: converging evidence from fMRI and frontotemporal lobar degeneration. Neuropsychologia 48, 3505-3512.
93. Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., et al. (2005). Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 57, 721-729.
94. Grossman, M., Powers, J., Ash, S., McMillan, C., Burkholder, L., Irwin, D., et al. (2012). Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. Brain Lang. doi: 10.1016/j.bandl.2012.10.005. [Epub ahead of print].
95. Grossman, M., Xie, S. X., Libon, D. J., Wang, X., Massimo, L., Moore, P., et al. (2008). Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology 70, 2036-2045.
96. Gunawardena, D., Ash, S., McMillan, C., Avants, B., Gee, J., and Grossman, M. (2010). Why are patients with progressive nonfluent aphasia nonfluent? Neurology 75, 588-594.
97. Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., and Trojanowski, J. Q. (2010). Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45, 30-40.
98. Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P., et al. (2000). Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimers Dis. 2, 199-206.
99. Hodges, J. R., Davies, R. R., Xuereb, J. H., Casey, B., Broe, M., Bak, T. H., et al. (2004). Clinicopathological correlates in frontotemporal dementia. Ann. Neurol. 56, 399-406.
100. Hodges, J. R., and Patterson, K. (2007). Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 6, 1004-1014.
101. Hoglinger, G. U., Melhem, N. M., Dickson, D. W., Sleiman, P. M., Wang, L. S., Klei, L., et al. (2011). Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699-705.
102. Hu, W. T., Chen-Plotkin, A., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M., et al. (2010a). Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 120, 385-399.
103. Hu, W. T., Chen-Plotkin, A., Grossman, M., Arnold, S. E., Clark, C. M., Shaw, L. M., et al. (2010b). Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 75, 2079-2086.
104. Hu, W. T., McMillan, C., Libon, D., Leight, S., Forman, M., Lee, V. M., et al. (2010c). Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology 75, 595-602.
105. Hu, W. T., Trojanowski, J. Q., and Shaw, L. M. (2011). Biomarkers in frontotemporal lobar degenerations-progress and challenges. Prog. Neurobiol. 95, 636-648.
106. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al. (1998). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
107. Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M., et al. (2012a). Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135, 807-818.
108. Irwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L. S., et al. (2012b). Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch. Neurol. 69, 1018-1025.
109. Irwin, D. J., McMillan, C. T., Brettschneider, J., Libon, D. J., Powers, J., Rascovsky, K., et al. (2013). Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 84, 163-169.
110. Jack, C. R. Jr., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128.
111. Jack, C. R. Jr., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., et al. (2012). Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch. Neurol. 69, 856-867.
112. Jin, K., Takeda, A., Shiga, Y., Sato, S., Ohnuma, A., Nomura, H., et al. (2006). CSF tau protein: a new prognostic marker for Guillain-Barre syndrome. Neurology 67, 1470-1472.
113. Josephs, K. A. (2008). Frontotemporal dementia and related disorders: deciphering the enigma. Ann. Neurol. 64, 4-14.
114. Josephs, K. A., Duffy, J. R., Strand, E. A., Whitwell, J. L., Layton, K. F., Parisi, J. E., et al. (2006a). Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 129, 1385-1398.
115. Josephs, K. A., Whitwell, J. L., Jack, C. R., Parisi, J. E., and Dickson, D. W. (2006b). Frontotemporal lobar degeneration without lobar atrophy. Arch. Neurol. 63, 1632-1638.
116. Kapaki, E., Paraskevas, G. P., Papageorgiou, S. G., Bonakis, A., Kalfakis, N., Zalonis, I., et al. (2008). Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord. 22, 47-53.
117. Kasai, T., Tokuda, T., Ishigami, N., Sasayama, H., Foulds, P., Mitchell, D. J., et al. (2009). Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 117, 55-62.
118. Kertesz, A., McMonagle, P., Blair, M., Davidson, W., and Munoz, D. G. (2005). The evolution and pathology of frontotemporal dementia. Brain 128, 1996-2005.
119. Kipps, C. M., Hodges, J. R., and Hornberger, M. (2010). Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the 'bvFTD phenocopy syndrome'. Curr. Opin. Neurol. 23, 628-632.
120. Knibb, J. A., Xuereb, J. H., Patterson, K., and Hodges, J. R. (2006). Clinical and pathological characterization of progressive aphasia. Ann. Neurol. 59, 156-165.
121. Knopman, D. S., Boeve, B. F., Parisi, J. E., Dickson, D. W., Smith, G. E., Ivnik, R. J., et al. (2005). Antemortem diagnosis of frontotemporal lobar degeneration. Ann. Neurol. 57, 480-488.
122. Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., et al. (2008). Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 131, 2957-2968.
123. Koedam, E. L., Van Der Vlies, A. E., Van Der Flier, W. M., Verwey, N. A., Koene, T., Scheltens, P., et al. (2012). Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Alzheimers Dement. doi: 10.1016/j.jalz.2011.12.007. [Epub ahead of print].
124. Koopman, K., Le Bastard, N., Martin, J. J., Nagels, G., De Deyn, P. P., and Engelborghs, S. (2009). Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem. Int. 55, 214-218.
125. Koric, L., Felician, O., Guedj, E., Hubert, A. M., Mancini, J., Boucraut, J., et al. (2010). Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer Dis. Assoc. Disord. 24, 278-283.
126. Krut, J. J., Zetterberg, H., Blennow, K., Cinque, P., Hagberg, L., Price, R. W., et al. (2013). Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J. Neurol. 260, 620-626.
127. Lee, S. E., Rabinovici, G. D., Mayo, M. C., Wilson, S. M., Seeley, W. W., Dearmond, S. J., et al. (2011). Clinicopathological correlations in corticobasal degeneration. Ann. Neurol. 70, 327-340.
128. Lewczuk, P., Zimmermann, R., Wiltfang, J., and Kornhuber, J. (2009). Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116, 1163-1167.
129. Libon, D. J., Rascovsky, K., Gross, R. G., White, M. T., Xie, S. X., Dreyfuss, M., et al. (2011). The Philadelphia Brief Assessment of Cognition (PBAC): a validated screening measure for dementia. Clin. Neuropsychol. 25, 1314-1330.
130. Luk, C., Compta, Y., Magdalinou, N., Marti, M. J., Hondhamuni, G., Zetterberg, H., et al. (2012). Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J. Neurochem. 123, 396-405.
131. Mackenzie, I. R., Neumann, M., Baborie, A., Sampathu, D. M., Du Plessis, D., Jaros, E., et al. (2011). A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111-113.
132. Mackenzie, I. R., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., et al. (2010). Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119, 1-4.
133. Massimo, L., Libon, D. J., Chandrasekaran, K., Dreyfuss, M., McMillan, C. T., Rascovsky, K., et al. (2013). Self-appraisal in behavioural variant frontotemporal degeneration. J. Neurol. Neurosurg. Psychiatry, 84, 148-153.
134. Massimo, L., Powers, C., Moore, P., Vesely, L., Avants, B., Gee, J., et al. (2009). Neuroanatomy of apathy and disinhibition in frontotemporal lobar degeneration. Dement. Geriatr. Cogn. Disord. 27, 96-104.
135. Matsuo, E. S., Shin, R. W., Billingsley, M. L., Van Devoorde, A., O'Connor, M., Trojanowski, J. Q., et al. (1994). Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13, 989-1002.
136. Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., et al. (2011). The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7, 386-395. e386.
137. Mattsson, N., Ruetschi, U., Pijnenburg, Y. A., Blankenstein, M. A., Podust, V. N., Li, S., et al. (2008). Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Mol. Med. Report. 1, 757-761.
138. McMillan, C. T., Avants, B., Irwin, D. J., Toledo, J. B., Wolk, D. A., Van Deerlin, V. M., et al. (2013). Can MRI screen for CSF biomarkers in neurodegenerative disease? Neurology, 80, 132-138.
139. McMillan, C. T., Brun, C., Siddiqui, S., Churgin, M., Libon, D., Yushkevich, P., et al. (2012a). White matter imaging contributes to the multimodal diagnosis of frontotemporal lobar degeneration. Neurology 78, 1761-1768.
140. McMillan, C. T., Rascovsky, K., Khella, M. C., Clark, R., and Grossman, M. (2012b). The neural basis for establishing a focal point in pure coordination games. Soc. Cogn. Affect. Neurosci. 7, 881-887.
141. Mesulam, M., Wicklund, A., Johnson, N., Rogalski, E., Leger, G. C., Rademaker, A., et al. (2008). Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann. Neurol. 63, 709-719.
142. Mesulam, M. M. (1982). Slowly progressive aphasia without generalized dementia. Ann. Neurol. 11, 592-598.
143. Mesulam, M. M. (2001). Primary progressive aphasia. Ann. Neurol. 49, 425-432.
144. NLM/NIH. (2012). Available online at: http://www.ncbi.nlm.nih.gov/pubmed/ [Accessed 10/27/12 2012].
145. Olsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., et al. (2005). Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336-345.
146. Ost, M., Nylen, K., Csajbok, L., Ohrfelt, A. O., Tullberg, M., Wikkelso, C., et al. (2006). Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67, 1600-1604.
147. Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., et al. (1997). Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt- Jakob disease. Neurosci. Lett. 225, 210-212.
148. Patel, S., Lee, E. B., Xie, S. X., Law, A., Jackson, E. M., Arnold, S. E., et al. (2012). Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS 9:7. doi: 10.1186/2045-8118-9-7
149. Pijnenburg, Y. A., Schoonenboom, N. S., Rosso, S. M., Mulder, C., Van Kamp, G. J., Van Swieten, J. C., et al. (2004). CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology 62, 1649.
150. Pijnenburg, Y. A., Schoonenboom, S. N., Mehta, P. D., Mehta, S. P., Mulder, C., Veerhuis, R., et al. (2007). Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 78, 735-737.
151. Rabinovici, G. D., Jagust, W. J., Furst, A. J., Ogar, J. M., Racine, C. A., Mormino, E. C., et al. (2008). Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann. Neurol. 64, 388-401.
152. Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477.
153. Rascovsky, K., Salmon, D. P., Hansen, L. A., and Galasko, D. (2008). Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsyconfirmed frontotemporal dementia and Alzheimer's disease. J. Int. Neuropsychol. Soc. 14, 373-383.
154. Renton, A. E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J. R., et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268.
155. Riemenschneider, M., Wagenpfeil, S., Diehl, J., Lautenschlager, N., Theml, T., Heldmann, B., et al. (2002). Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 58, 1622-1628.
156. Rosso, S. M., Van Herpen, E., Pijnenburg, Y. A., Schoonenboom, N. S., Scheltens, P., Heutink, P., et al. (2003). Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch. Neurol. 60, 1209-1213.
157. Schmidt, M. L., Gur, R. E., Gur, R. C., and Trojanowski, J. Q. (1988). Intraneuronal and extracellular neurofibrillary tangles exhibit mutually exclusive cytoskeletal antigens. Ann. Neurol. 23, 184-189.
158. Schoonenboom, N. S., Pijnenburg, Y. A., Mulder, C., Rosso, S. M., Van Elk, E. J., Van Kamp, G. J., et al. (2004). Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580-1584.
159. Schoonenboom, N. S., Reesink, F. E., Verwey, N. A., Kester, M. I., Teunissen, C. E., Van De Ven, P. M., et al. (2012). Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
160. Seguin, J., Formaglio, M., Perret-Liaudet, A., Quadrio, I., Tholance, Y., Rouaud, O., et al. (2011). CSF biomarkers in posterior cortical atrophy. Neurology 76, 1782- 1788.
161. Seppala, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., et al. (2012). CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78, 1568-1575.
162. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413.
163. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., et al. (2011). Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 121, 597-609.
164. Shi, J., Shaw, C. L., Du Plessis, D., Richardson, A. M., Bailey, K. L., Julien, C., et al. (2005). Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol. 110, 501-512.
165. Sjogren, M., Davidsson, P., Tullberg, M., Minthon, L., Wallin, A., Wikkelso, C., et al. (2001). Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 70, 624-630.
166. Sjogren, M., Minthon, L., Davidsson, P., Granerus, A. K., Clarberg, A., Vanderstichele, H., et al. (2000a). CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural Transm. 107, 563-579.
167. Sjogren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., and Wallin, A. (2000b). Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54, 1960-1964.
168. Snowden, J., Neary, D., and Mann, D. (2007). Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 114, 31-38.
169. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292.
170. Steinacker, P., Hendrich, C., Sperfeld, A. D., Jesse, S., Von Arnim, C. A., Lehnert, S., et al. (2008). TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 65, 1481-1487.
171. Tapiola, T., Alafuzoff, I., Herukka, S. K., Parkkinen, L., Hartikainen, P., Soininen, H., et al. (2009). Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382-389.
172. Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., et al. (2012). CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 124, 23-35.
173. Trojanowski, J. Q., and Growdon, J. H. (1998). A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. J. Neuropathol. Exp. Neurol. 57, 643-644.
174. Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., et al. (2010). Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 6, 230-238.
175. Turner, R. S., Kenyon, L. C., Trojanowski, J. Q., Gonatas, N., and Grossman, M. (1996). Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Ann. Neurol. 39, 166-173.
176. Van Deerlin, V. M., Sleiman, P. M., Martinez-Lage, M., Chen-Plotkin, A., Wang, L. S., Graff-Radford, N. R., et al. (2010). Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 42, 234-239.
177. Van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A., Van Der Flier, W. M., et al. (2011). Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin. Chem. Lab. Med. 49, 353-366.
178. Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjogren, M., et al. (2000). Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49-52.
179. Verwey, N. A., Kester, M. I., Van Der Flier, W. M., Veerhuis, R., Berkhof, H., Twaalfhoven, H., et al. (2010). Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J. Alzheimers Dis. 20, 445-452.
180. Wang, L. S., Leung, Y. Y., Chang, S. K., Leight, S., Knapik-Czajka, M., Baek, Y., et al. (2012). Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. J. Alzheimers Dis. 31, 439-445.
181. Weiner, M. W., Aisen, P. S., Jack, C. R. Jr., Jagust, W. J., Trojanowski, J. Q., Shaw, L., et al. (2010). The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 6, 202-211 e207.
182. Whitwell, J. L., Weigand, S. D., Boeve, B. F., Senjem, M. L., Gunter, J. L., Dejesus-Hernandez, M., et al. (2012). Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 135, 794-806.
183. Zhukareva, V., Sundarraj, S., Mann, D., Sjogren, M., Blenow, K., Clark, C. M., et al. (2003). Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol. 105, 469-476.
184. Zhukareva, V., Vogelsberg-Ragaglia, V., Van Deerlin, V. M., Bruce, J., Shuck, T., Grossman, M., et al. (2001). Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann. Neurol. 49, 165-175.